Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension.
Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension.
复制标题
大麻素受体 2 - 血红素加氧酶途径的功能相关性:减轻门脉高压的新靶点
DOI:
10.1016/j.lfs.2013.08.018
复制
发表时间:
2013
期刊:
影响因子:
6.1
通讯作者:
Gerbes A.L.
中科院分区:
文献类型:
--
作者:
Steib C.J;Gmelin L;Pfeiler S;Schewe J;Brand S;Göke B;Gerbes A.L.
AimsIn liver cirrhosis, inflammation triggers portal hypertension. Kupffer cells (KC) produce vasoconstrictors upon activation by bacterial constituents. Here, we hypothesize that the anti-inflammatory action of the cannabinoid receptor 2 (CB2) agonists JWH-133 and GP 1a attenuate portal hypertension.Main methodsIn vivomeasurements of portal pressures and non-recirculating liver perfusions were performed in rats 4 weeks after bile duct ligation (BDL). Zymosan (150 μg/ml, isolated liver perfusion) or LPS (4 mg/kg b.w.,in vivo) was infused to activate the KC in the absence or presence of JWH-133 (10 mg/kg b.w.), GP 1a (2.5 mg/kg b.w.) or ZnPP IX (1 μM). Isolated KC were treated with Zymosan (0.5 mg/ml) in addition to JWH-133 (5 μM). The thromboxane (TX) B2levels in the perfusate and KC media were determined by ELISA. Heme oxygenase-1 (HO-1) and CB2were analyzed by Western blot or confocal microscopy.Key findingsJWH-133 or GP 1a pre-treatment attenuated portal pressures following KC activation in all experimental settings. In parallel, HO-1 expression increased with JWH-133 pre-treatment. However, the inhibition of HO-1 enhanced portal hypertension, indicating the functional role of this novel pathway. In isolated KC, the expression of CB2and HO-1 increased with Zymosan, LPS and JWH-133 treatment while TXB2production following KC activation was attenuated by JWH-133 pre-treatment.SignificanceJWH-133 or GP 1a treatment attenuates portal hypertension. HO-1 induction by JWH-133 plays a functional role. Therefore, the administration of JWH-133 or GP 1a represents a promising new treatment option for portal hypertension triggered by microbiological products.
登录
查看更多内容
影响因子:
3.1
作者:
C. Steib;M. Bilzer;Josef M. Härtl;Frigga Beitinger;V. Gülberg;B. Göke;A. Gerbes
通讯作者:
A. Gerbes
影响因子:
25.7
作者:
Miller,AndrewM;Masrorpour,Mina;Klaus,Christian;Zhang,JianX
通讯作者:
Zhang,JianX
影响因子:
7.3
作者:
Correa, F;Mestre, L;Guaza, C
通讯作者:
Guaza, C
影响因子:
2.8
作者:
O'Sullivan, S. E.;Kendall, D. A.
通讯作者:
Kendall, D. A.
影响因子:
25.7
作者:
Lin, Han-Chieh;Yang, Ying-Ying;Lee, Shou-Dong
通讯作者:
Lee, Shou-Dong